<DOC>
	<DOCNO>NCT02595281</DOCNO>
	<brief_summary>HE4 sensitive marker CA-125 patient ovarian cancer . The interest serum HE4 surgery demonstrate predict overall survival interest also show combination CA-125 ( ROMA algorithm ) identify high risk patient . To date , study show clearly predictive potential serum HE4 early relapse biomarker ovarian cancer .</brief_summary>
	<brief_title>HE4 Relapse Biomarker Ovarian Cancers</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Ovarian adenocarcinoma stage IIIa , IIIb IV pleural , cytologically histologically proven Patient schedule undergo neoadjuvant chemotherapy base platinum follow surgery adjuvant chemotherapy Age ≥ 18 year . Performance status ECOG &gt; = 2 Adequate haemoglobin rate ≥ 10 g/dL Ability provide write informed consent Patient 's legal capacity consent study participation Any previous treatment platinum ovarian carcinoma Patient visceral metastasis Contraindication blood test Contraindication surgery Contraindication bevacizumab treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Ovarian Carcinoma</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>ROMA</keyword>
	<keyword>Ca125</keyword>
	<keyword>HE4</keyword>
	<keyword>biomarker</keyword>
</DOC>